2.Company name:Microbio (Shanghai) Co.,Ltd.

3.Relationship to the Company (please enter ”head office” or

”subsidiaries”):subsidiary

4.Reciprocal shareholding ratios:NA

5.Cause of occurrence:

(1)New drug name or code:FESPIXON (research code: ON101)

(2)Purpose:

A. Treatment of diabetic foot ulcers.

B. Information Website:https://www.nmpa.gov.cn/

(3)Planned development stages：Not applicable

(4)Current development stage:

A. File application/approved/disapproved/Each of clinical trials

(include interim analysis):

a. The new drug application (NDA) of FESPIXON, the new drug in

treatment of diabetic foot ulcers, has been approved by National

Medical Products Administration (NMPA  ) in China. The approved

generic name is Xianglei Tangzu Gao, and the approval number is

ZC20230001.

b. Microbio (Shanghai) Co., Ltd. owns the exclusive right to

commercialize Fespixon in China, Hong Kong and Macau.

B. Once disapproved by competent authority or each of clinical trials

(include interim analysis) results less than statistically

significant sense, the risks and the associated measures the

Company may occur: NA

C. After obtaining official approval or the results (include interim

analysis) which are statistically significant, the future strategy:

Microbio (Shanghai) Co., Ltd. will be responsible for the marketing

and sales of FESPIXON.

D. Accumulated investment expenditure incurred: No disclosure of the

investment expenditure at the moment in consideration of the future

marketing strategies.

(5) Upcoming development plan:

A. Scheduled completion date:Not applicable

B. Estimate responsibilities:Microbio (Shanghai) Co., Ltd. shall pay

Oneness Biotech milestone payment and a certain percentage of

royalties based on sales according to the agreement.

(6)Market:

Diabetes has evolved from a rare disease to an epidemic one in China.

According to the International Diabetes Federation (IDF) data in 2021,

there were 141 million adult diabetic patients in China, with a

prevalence rate of 13.0%. The increase in diabetic foot ulcers has also

been significant, at approximately 6.3% prevalence globally. Among

Chinese diabetic patients at the age of 50 years or above, the incidence

of diabetic foot ulcers reached 8.1%. It is estimated there are over 7.5

million DFU patients in China. The amputation of a diabetic limb occurs

every 20 seconds worldwide. The mortality rate of DFU patients is 11% per

year while it is even higher, reaching 22% if they had an amputation. The

five-year mortality rate for DFU patients after amputation is

approximately 50%, posing a severe threat to their lives. The costs of

treating diabetic foot ulcers is enormous, accounting for approximately

one-third of the total diabetes-related medical expenses, causing

significant burdens on patients, families, hospitals, and society.

6.Countermeasures:None

7.Any other matters that need to be specified(the information

disclosure also meets the requirements of Article 7, subparagraph 9

of the Securities and Exchange Act Enforcement Rules, which brings

forth a significant impact on shareholders rights or the price of

the securities on public companies.):

(1)FESPIXON is the first Class 1.1 natural new drug approved in China and

also the only new drug approved specifically for the treatment of diabetic

foot ulcers in China.

(2)According to Guidelines by Taipei Exchange on the Material Information

Announced by Listed and OTC Companies, new drug development companies

shall make public announcement when filing application for clinical trials

to domestic or overseas regulatory authorities, receiving approval or

disapproval, obtaining the statistical date of endpoints in each clinical

trial (including interim analysis), or receiving approval or disapproval

on drug license application.

(3)It takes considerable time and expenses to develop a new drug of which

success can’t be guaranteed. Investors shall bear such investment risk

that warrants careful assessment before making investment decisions.